Effects of Narrative Writing Duration and Post-writing Processing Instructions on PTSD
NCT ID: NCT01773811
Last Updated: 2014-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
49 participants
INTERVENTIONAL
2012-02-29
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Examining Written Disclosure as a Treatment for Post-Traumatic Stress Disorder
NCT00862498
Narrative Exposure Based Intervention For Post-Traumatic Stress Disorder
NCT03229525
Examining the Effectiveness of an Early Psychological Intervention to Prevent Post-Traumatic Stress Disorder
NCT00895518
Information Processing Modification in PTSD (Oct. 18)
NCT00601952
Written Versus Verbal Brief Cognitive Behavioral Exposure Therapy
NCT04000217
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Individuals will write objectively about the events of their day.
No interventions assigned to this group
Narrative Writing: Trauma-Assigned
Trauma-assigned: Individuals will write about their most traumatic life experience and be instructed to continue to think about their writing topic in the weeks following writing.
Narrative Writing: Trauma-Assigned
Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
Narrative Writing: Trauma-Spontaneous
Individuals will write about their most traumatic life experience but will not be given further instructions for processing. Any additional processing about their writing topic in the weeks following writing will be considered spontaneous.
Narrative Writing: Trauma-Spontaneous
Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Narrative Writing: Trauma-Assigned
Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
Narrative Writing: Trauma-Spontaneous
Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently experiencing clinically significant levels of PTSD symptoms
Exclusion Criteria
* On medication that is not stable (i.e. medication has been changed within the past 6 weeks)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Mississippi, Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tom Lombardo, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Mississippi, Oxford
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Mississippi
University, Mississippi, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMO-0004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.